the company was under the radar and oversold for a long time due to the CRL last year. After the long-awaited approval, it still hasn't leaked out what this event means for the future of cancer therapy. The media is not reporting on it, so there is no hype. If a partnership with Merck is announced (or another pharmaceutical giant), it will soon be leaked to the masses. FYI: Anktiva has a 71% success rate in the treatment of bladder cancer (WITHOUT adverse events), compared to Merck's Keytruda, the current standard therapy, with only 42% and sometimes severe side effects and a shorter duration of action
Wanted to expand my position the other day when they were at just under € 2, but then they were already slowly shooting up again. Stupid timing until the money was on deposit :(
Why did you sell at this point? Uptrend on short timeframe is still in tact. The saucer is only just being filled and resistance is still to come 🙂 In addition, a cooperation is to be published ... @ShovelStocks certainly knows more about it.
